The Univeristy of Melbourne The Royal Melbourne Hopspital

A joint venture between The University of Melbourne and The Royal Melbourne Hospital

Dr Miranda Pitt

Dr Miranda Pitt

(03) 8344 9927 | miranda.pitt@unimelb.edu.au

Position:
Postdoctoral Research Officer
Theme(s):
Antimicrobial Resistance
Discipline(s):
Discovery Research, Computational Science and Genomics, Public Health, Clinical and health systems research
Unit(s):
Department of Microbiology and Immunology (DMI)
Lab Group(s):
Coin group

Miranda completed her Bachelor of Biomedical Science degree at the University of Queensland (UQ) in 2013, which focused on Infectious Diseases, Immunology and Genetics. In 2014, she began her PhD at the Institute for Molecular Bioscience, UQ. Her research delved into understanding the mode of action of last resort antibiotics against multidrug-resistant Gram-negative bacteria and the genetic basis underpinning resistance. Her PhD was awarded in 2018 and she continued this work as a Postdoctoral Researcher. Since 2019, she works in Professor Lachlan Coin’s group at the University of Melbourne researching antimicrobial resistance, bacterial genomics and transcriptomics.

  • Key Achievements
      • Awarded Honours Class I for her undergraduate degree.
      • Research has been published in various Microbiology and Genomics related journals.
      • Presented her work at multiple national and international conferences, including London Calling (2018, Invited speaker) and the Australasian Genomic Technologies Association (2019, speaker, travel award, best ECR poster award).
      • Received first place at HealthHack (2016).
      • Represented Queensland in the national final of Falling Walls Lab Australia (2019).
      • She has also been teaching since 2014 and received a tutor award (ranked top 10%, 2016, SCMB, University of Queensland).
    Research Groups
    • Coin group

      The Coin Group develops genomic and transcriptomic tools to develop biomarkers for rapid characterization of disease state and prediction of drug susceptibility, with the aim of decreasing the time taken from hospital admission to administering the right treatment. We currently focus on infectious disease as well as cancer.    


      Lab Team